[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"overdose-prevention\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:overdose-prevention":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100648636","clinician-practice-companion-to-address-youth-substance-use-100648636",false,"NCT07725289","Clinician Practice Companion to Address Youth Substance Use","Inclusion Criteria:\n\n* Ages 14 to 24 years.\n* Uses drugs or alcohol (past year).\n* Receiving care at a participating study site.\n\nExclusion Criteria:\n\n* Cognitive limitations or intellectual disabilities that prevent provision of informed consent.\n* Any medical or psychiatric condition causing acute distress or requiring emergency evaluation.\n* Current membership on a study Community Advisory Board.",true,"ALL","14 Years","24 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Substance use, including the use of opioids, cannabis, and other drugs, is common among adolescents and young adults, and overdose has become a leading cause of death among youth in Canada and the United States. Many young people who use substances also experience co-occurring mental health concerns. Evidence-based approaches to youth substance use care exist, including harm reduction, overdose prevention (such as naloxone and take-home drug testing strips), and medications for addiction treatment. These approaches remain adult-oriented, however, unevenly implemented in youth-serving settings, and insufficiently centered on the needs and goals of youth and their families.\n\nThis study develops and pilot tests a written \"practice companion\" that helps clinicians and other trusted adults provide developmentally appropriate substance use care to youth ages 14 to 24 in hospital and community settings. The practice companion offers practical, easy-to-use guidance organized by substance and by pattern of use. It addresses cannabis and other substances that youth commonly use and that clinicians frequently seek support with, alongside a strong focus on overdose prevention through its core elements: naloxone, take-home drug testing strips, harm reduction education, and medications for opioid use disorder. It also attends to co-occurring mental health needs and to how gender, sexuality, housing instability, and other social and structural contexts shape substance use and care.\n\nThe research team will first interview youth who use substances, their families and caregivers, and clinicians to learn how each element of care should be adapted for young people. The team will then produce the practice companion and pilot test it with 60 youth across three sites, in British Columbia, Québec, and Massachusetts. After receiving care guided by the practice companion, youth will complete an interview about whether the care was relevant, useful, appropriate, and acceptable. Families and clinicians will also be interviewed to assess how feasible, sustainable, and faithful to its design the practice companion is in practice.\n\nThroughout the study, the team will work closely with youth and families who have lived experience through a community-based participatory research approach that includes Community Advisory Boards. The work centers equity for Black, Indigenous, and other racialized youth, Two-Spirit and LGBTQ+ youth, and youth experiencing housing instability. Findings will guide a larger future study of the practice companion's effectiveness.",[27,28,29,30,31,32,33,34],"Substance Use","Substance-Related Disorders","Adolescent Substance Use","Cannabis Use","Opioid Use Disorder","Drug Overdose","Overdose Prevention","Co-occurring Mental Health Conditions",[36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57],"Adolescents","Young adults","Youth","Substance use","Substance use care","Cannabis","Naloxone","Harm reduction","Take-home drug testing strips","Fentanyl","Medications for opioid use disorder (MOUD)","Buprenorphine","Methadone","Overdose prevention","Co-occurring mental health","Youth- and family-centred care","Patient-reported outcomes","Health equity","Implementation science","ADAPT-ITT","Community-based participatory research","Toolkit","NOT_YET_RECRUITING","2026-07-23",{"date":61,"type":62},"2026-07-27","ACTUAL",{"date":64,"type":21},"2027-01",{"date":66,"type":21},"2029-12",{"name":68,"class":69},"Massachusetts General Hospital","OTHER",5]